Provides an integrated care platform that combines online consultations with EHR integration, automated document processing, and data-driven analytics to streamline primary care workflows. By reducing manual tasks, improving triage efficiency, and enabling seamless collaboration across care teams, it helps over 200 practices deliver better patient outcomes while saving clinical staff an hour daily.

Aware provides a comprehensive security platform designed to monitor and manage risks across modern digital collaboration environments. The service integrates advanced data loss prevention (DLP) and compliance monitoring for platforms like Slack and Microsoft Teams. This allows organizations to maintain regulatory adherence and protect sensitive intellectual property within their communication channels.

Awell provides a Care Operations platform designed to streamline complex healthcare workflows and reduce system inefficiencies. The platform learns from every interaction to deliver smarter, more responsive patient and provider care experiences. This service helps healthcare organizations master their operational processes to improve overall system performance.

Biomia utilizes synthetic biology techniques to develop plant-derived natural products aimed at treating unmet medical conditions. The company focuses on creating effective therapeutic solutions that address gaps in current medical treatments.

CoSyne Therapeutics applies polymathic Artificial Intelligence to accelerate precision medicine drug discovery, focusing specifically on underserved brain diseases. The company utilizes advanced computational methods to identify novel therapeutic targets and develop treatments for complex neurological conditions. This approach aims to significantly advance the pipeline for brain cancer and other challenging brain disorders.

Cradle offers an AI‑driven protein engineering platform that learns from a user’s experimental data and public datasets to generate and rank protein candidates across multiple objectives such as activity, binding affinity, stability, and expression. The cloud‑hosted workspace automates library design, runs large‑scale in‑silico simulations, and provides interactive visualizations to help scientists iterate rapidly, reducing the number of experimental rounds needed to meet target specifications.

Enveda Biosciences utilizes a platform that rapidly purifies and characterizes natural molecules, enabling the discovery of new drugs at four times the industry average speed. By unlocking the chemical potential of the vast majority of the natural world, Enveda addresses the challenge of slow and costly drug development processes.

ExpressionEdits utilizes its Genetic Syntax Engine, an AI-driven computational platform, to optimize transgene design through intronization. This technology precisely edits genetic grammar to unlock the expression of previously inaccessible proteins for therapeutic applications. The platform enhances gene expression and potency, enabling the development of high-value protein therapeutics and optimizing existing gene therapy constructs.

Hedera Dx provides a liquid biopsy solution that enables hospital laboratories to perform CE-IVDR compliant tumor profiling in-house using circulating tumor DNA (ctDNA). Their integrated software and assay panel streamline the workflow from blood draw to clinical reporting for personalized oncology treatment selection. This platform simplifies the adoption of NGS-based liquid biopsies, offering actionable insights for patient care.

Huminly utilizes proprietary enzyme engineering to achieve high-efficiency, textile-to-textile recycling of mixed fiber waste. This enzymatic process separates polyester from cotton, yielding purified monomers and fibers suitable for reuse. The technology offers cost parity with virgin materials and significant operational advantages over traditional chemical recycling methods.

Inductive Bio provides a virtual laboratory platform that uses AI chemistry assistants and ADMET models to predict molecular behavior in the body. This capability allows drug discovery teams to run millions of _in silico_ experiments to surface the strongest hypotheses for wet lab testing. The platform accelerates development candidate selection by front-loading critical safety and efficacy insights before synthesis.

Junction provides a standards‑based API that consolidates lab ordering across the U.S. with real‑time data from over 300 wearables and medical devices. The platform automates order routing, result delivery, patient reminders, and device data normalization, offering a secure, HIPAA‑compliant analytics dashboard for digital health clinics, wellness platforms, and EHR SaaS providers.

Kano Therapeutics develops genetic payloads using circular single-stranded DNA (ssDNA) for the targeted correction of long stretches of DNA. This novel ssDNA biomaterial offers precise, safe insertion capabilities that complement existing gene editing tools like CRISPR. Their fermentation-based production method enables cost-effective manufacturing of these optimized DNA donor templates for genomic engineering applications.

Kernalbio develops mRNA therapies that enable selective translation of therapeutic proteins in target cells, utilizing a clinically validated delivery system to enhance tissue specificity. This approach addresses the limitations of traditional mRNA design, which often fails to effectively target specific cells within tissue and tumor microenvironments.

Lindus Health operates as an anti-CRO, utilizing a proprietary software platform and access to 30 million Electronic Health Records to execute end-to-end clinical trials with fixed pricing and milestone-based payments. By streamlining study design, patient recruitment, and data management, Lindus delivers trials up to three times faster than traditional CROs, ensuring timely access to new treatments for patients.

Portal Biotech provides a bench‑top nanopore platform that detects individual proteins, peptides, and small molecules as they pass through a nanoscale pore, generating electrical signatures that are decoded by machine‑learning algorithms into full‑length sequences and modification details. The system offers real‑time, quantitative results across three assay modes—including intact‑protein sequencing and peptide‑fragment analysis—enabling researchers in academia and biopharma to characterize proteoforms and metabolites with high sensitivity and low cost.

Recursion is a clinical-stage TechBio company that utilizes a synchronized combination of hardware, software, and data to industrialize drug discovery, leveraging over 60 petabytes of biological and chemical data. The platform enables rapid profiling of gene and compound relationships, addressing the inefficiencies in traditional drug development processes.

Rivia provides a unified data platform that ingests, harmonizes, and structures fragmented clinical trialdata from any source into trial-specific models. Its AI agents continuously monitor data quality, detect issues, and automate resolution workflows, while a conversational interface enables real-time visual analytics and patient-level insights. This integrated intelligence layer supports biopharma teams in making faster, data-driven decisions throughout trial operations.

Sensible Bio operates a cell-based mRNA design and manufacturing platform to produce pure mRNA therapeutics. This approach overcomes limitations of synthetic mRNA by yielding products with low immunogenicity. The platform enables a new paradigm for design-based biology in therapeutic development.

Seqera provides a unified bioinformatics platform that integrates data, pipelines, and compute infrastructure for scientific teams. It enables the building and scaling of reproducible workflows across on-premises systems and major cloud providers like AWS, GCP, and Azure. The platform facilitates high-throughput computation and secure collaboration, accelerating research from discovery to development.

Serna Bio offers an AI‑driven platform that designs, synthesizes, and screens small‑molecule modulators of RNA translation and splicing using deep‑learning predictions and massively multiplexed cell‑based assays. The closed‑loop workflow delivers quantitative SAR and selectivity data, enabling pharmaceutical and biotech R&D teams to discover therapeutics for previously undruggable RNA targets.

Tandem Health develops an ambient AI scribe that automatically generates medical notes during patient consultations, allowing healthcare providers to focus entirely on patient care. This technology reduces administrative burdens, enhances documentation accuracy, and improves patient engagement by capturing detailed clinical interactions in real time.

The startup develops a drug discovery platform that integrates human pluripotent stem cell disease models with AI-driven data generation to enhance predictive validity in early-stage drug development. By providing cost-effective insights into therapeutic targets, the platform increases the likelihood of successful drug discovery outcomes.

Valinor offers an AI‑driven platform that unifies diverse omics, imaging, and clinical datasets—such as single‑cell RNA‑seq, ATAC‑seq, whole‑genome sequencing, proteomics, spatial omics, radiology, histopathology, ctDNA, and treatment histories—into a single analytical workspace. The platform creates automated patient simulations and predictive models to forecast disease progression, therapeutic response, and biomarker relevance, helping pharmaceutical and biotech teams prioritize drug candidates and reduce late‑stage failures. Results are delivered via interactive dashboards, APIs, and SDKs that integrate with existing R&D pipelines.